ValamAi Limited (“ValamAi”), a clinical-stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the issuance of a Notice of Allowance for its first Composition of Matter patent covering its innovative signal peptide technology. This achievement represents a significant milestone in ValamAi's mission to advance RNA-based therapeutics and expand its intellectual property portfolio globally.

ValamAi highlighted “Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative therapeutic potential in vivo,” the peer-reviewed publication underpinning VMB-100, ValamAi's lead engineered IGF-I mRNA candidate. The preclinical data demonstrate accelerated functional recovery and tissue regeneration, supporting the ongoing clinical development of the program in stress urinary incontinence.

ValamAi Limited today announced that Prof. Friedrich Metzger has joined its Scientific Advisory Board. Prof. Metzger co-invented VMB-100, ValamAi's engineered IGF-1 mRNA therapeutic, and previously led preclinical development of Risdiplam (Evrysdi™) at Roche, an FDA/EMA-approved oral therapy for spinal muscular atrophy. He brings more than 18 years of pharma and biotech R&D experience to ValamAi's platform and pipeline strategy.

ValamAi Limited today announced that regulators have cleared its Investigational New Drug (IND) application for VMB-100, a next-generation mRNA-encoded therapeutic candidate, clearing the way for a planned Phase IIa clinical study.